An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma

Bispecific antibody therapies, primarily targeting B-cell maturation antigen (BCMA), have shown remarkable outcomes in the treatment of heavily pretreated patients with multiple myeloma (MM). However, there are no current head-to-head trials informing practice for selection or sequencing of optimal T cell redirection strategies in later lines of therapy. Linvoseltamab is a novel BCMA-targeted bispecific antibody that was recently evaluated in the phase 1/2 LINKER-MM1 trial and is currently pending formal regulatory approval.

In this drug evaluation, we review efficacy and toxicity profiles of linvoseltamab in the context of currently approved bispecific antibody therapies for MM. Specifically, we highlight differences in dosing strategy, cytokine release syndrome (CRS) kinetics, and indirect efficacy comparisons between trials of linvoseltamab and other bispecific antibodies.

Linvoseltamab has a similar efficacy profile with favorable CRS incidence and time-to-onset compared to other approved bispecific antibodies. Pending final regulatory approval and labeling, further real-world analyses are needed to evaluate its final role in the evolving landscape of T cell redirection therapy for MM.